TY - JOUR
T1 - Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders
AU - Sofias, Alexandros Marios
AU - De Lorenzi, Federica
AU - Peña, Quim
AU - Azadkhah Shalmani, Armin
AU - Vucur, Mihael
AU - Wang, Jiong-Wei
AU - Kiessling, Fabian
AU - Shi, Yang
AU - Consolino, Lorena
AU - Storm, Gert
AU - Lammers, Twan
N1 - Funding Information:
A.M.S., F.DL., Y.S. and T.L., acknowledge financial support from the European Research Council (ERC: Meta-Targeting (864121)), the European Union (European Fund for Regional Development: TAKTIRA (EFRE-0801767)), the German Research Foundation (DFG: LA 2937/4-1, SH 1223/1-1, SFB/TRR57, SFB1066, GRK/RTG 2375 (Tumor-targeted Drug Delivery; Project number: 331065168)), the German Federal Ministry of Education and Research (BMBF: PP-TNBC, Project number: 16GW 0319K), and the Excellence Strategy of the Federal Government and the Länder (G:(DE-82)EXS-SF-OPSF580). L.C. acknowledges the Italian Association for Cancer Research (AIRC) fellowship for abroad “Monica Broggi”. J.W.W. and G.S. acknowledge funding from the Singapore Ministry of Health’s National Medical Research Council (NMRC/OFYIRG/0081/2018) and the National University of Singapore NanoNASH Program (NUHSRO/2020/002/NanoNash/LOA).
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/8
Y1 - 2021/8
N2 - Fibrosis is a common denominator in many pathologies and crucially affects disease progression, drug delivery efficiency and therapy outcome. We here summarize therapeutic and diagnostic strategies for fibrosis targeting in atherosclerosis and cardiac disease, cancer, diabetes, liver diseases and viral infections. We address various anti-fibrotic targets, ranging from cells and genes to metabolites and proteins, primarily focusing on fibrosis-promoting features that are conserved among the different diseases. We discuss how anti-fibrotic therapies have progressed over the years, and how nanomedicine formulations can potentiate anti-fibrotic treatment efficacy. From a diagnostic point of view, we discuss how medical imaging can be employed to facilitate the diagnosis, staging and treatment monitoring of fibrotic disorders. Altogether, this comprehensive overview serves as a basis for developing individualized and improved treatment strategies for patients suffering from fibrosis-associated pathologies.
AB - Fibrosis is a common denominator in many pathologies and crucially affects disease progression, drug delivery efficiency and therapy outcome. We here summarize therapeutic and diagnostic strategies for fibrosis targeting in atherosclerosis and cardiac disease, cancer, diabetes, liver diseases and viral infections. We address various anti-fibrotic targets, ranging from cells and genes to metabolites and proteins, primarily focusing on fibrosis-promoting features that are conserved among the different diseases. We discuss how anti-fibrotic therapies have progressed over the years, and how nanomedicine formulations can potentiate anti-fibrotic treatment efficacy. From a diagnostic point of view, we discuss how medical imaging can be employed to facilitate the diagnosis, staging and treatment monitoring of fibrotic disorders. Altogether, this comprehensive overview serves as a basis for developing individualized and improved treatment strategies for patients suffering from fibrosis-associated pathologies.
KW - Atherosclerosis
KW - Cancer
KW - Cardiovascular disease
KW - Diabetes
KW - Drug targeting
KW - Fibrosis
KW - Imaging
KW - Liver
KW - Nanomedicine
KW - Viral infection
UR - http://www.scopus.com/inward/record.url?scp=85108954322&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2021.113831
DO - 10.1016/j.addr.2021.113831
M3 - Review article
C2 - 34139255
AN - SCOPUS:85108954322
SN - 0169-409X
VL - 175
JO - Advanced drug delivery reviews
JF - Advanced drug delivery reviews
M1 - 113831
ER -
